BACKGROUND: To evaluate the prognostic implication of cancer stem cell markers in pancreac ductal adenocarcinoma (PDAC), the expression of CD133 and nestin were investigated in a series of PDAC patients in relation to the survival rate. METHODS: This series included 42 cases of PDAC patients and evaluated the stem cell markers CD133 and nestin expression detected by immunohistochemistry. The presence of immunopositive tumor cells considering intensity and area was evaluated and interpreted in comparison to the patients' clinicopathological and survival data. RESULTS: Twenty eight cases (66.7%) showed high CD133 expression. The CD133 expression was mainly identified in the apical border of the tumor cell, but aberrant expression in the cytoplasmic or perinuclear location was also noted. High nestin expression in tumor cells were found in only 2 cases, but high nestin expression along perinuerial or stromal region was found in 15 cases (35.7%). There was no correlation between CD133, nestin expression and gemcitabine resistance. Statistically significant difference was found in patient survival in N stage (p=0.007), and CD133 expression (p= 0.014) in univariate analysis. Nestin expression wan not statistically significant, but it was helpful to identify the perineurial invasion. In Cox-regression hazard model stratified by age and sex for multivariable analysis, AJCC stage and CD133 were independent prognostic factors for overall survival. CONCLUSIONS: CD133 expression is upregulated in PDAC that is related to poor prognosis, and treatment targeted the CD133 positive cancer/cancer stem cells might be a promising therapeutic strategy for this patients.
BACKGROUND: To evaluate the prognostic implication of cancer stem cell markers in pancreac ductal adenocarcinoma (PDAC), the expression of CD133 and nestin were investigated in a series of PDAC patients in relation to the survival rate. METHODS: This series included 42 cases of PDAC patients and evaluated the stem cell markers CD133 and nestin expression detected by immunohistochemistry. The presence of immunopositive tumor cells considering intensity and area was evaluated and interpreted in comparison to the patients' clinicopathological and survival data. RESULTS: Twenty eight cases (66.7%) showed high CD133 expression. The CD133 expression was mainly identified in the apical border of the tumor cell, but aberrant expression in the cytoplasmic or perinuclear location was also noted. High nestin expression in tumor cells were found in only 2 cases, but high nestin expression along perinuerial or stromal region was found in 15 cases (35.7%). There was no correlation between CD133, nestin expression and gemcitabine resistance. Statistically significant difference was found in patient survival in N stage (p=0.007), and CD133 expression (p= 0.014) in univariate analysis. Nestin expression wan not statistically significant, but it was helpful to identify the perineurial invasion. In Cox-regression hazard model stratified by age and sex for multivariable analysis, AJCC stage and CD133 were independent prognostic factors for overall survival. CONCLUSIONS:CD133 expression is upregulated in PDAC that is related to poor prognosis, and treatment targeted the CD133 positive cancer/cancer stem cells might be a promising therapeutic strategy for this patients.
Entities:
Keywords:
CD133; Pancreatic ductal adenocarcinoma; cancer stem cell; nestin; prognosis
Authors: Maria-Theresa Mueller; Patrick C Hermann; Juliane Witthauer; Belen Rubio-Viqueira; Simon F Leicht; Stephan Huber; Joachim W Ellwart; Mona Mustafa; Peter Bartenstein; Jan G D'Haese; Michael H Schoenberg; Frank Berger; Karl-Walter Jauch; Manuel Hidalgo; Christopher Heeschen Journal: Gastroenterology Date: 2009-06-06 Impact factor: 22.682
Authors: Wilson Petrushnko; Justin S Gundara; Philip R De Reuver; Greg O'Grady; Jaswinder S Samra; Anubhav Mittal Journal: HPB (Oxford) Date: 2016-07-14 Impact factor: 3.647
Authors: Alice Nomura; Vineet K Gupta; Patricia Dauer; Nikita S Sharma; Vikas Dudeja; Nipun Merchant; Ashok K Saluja; Sulagna Banerjee Journal: Mol Cancer Res Date: 2017-09-28 Impact factor: 5.852
Authors: Jan Skoda; Marketa Hermanova; Tomas Loja; Pavel Nemec; Jakub Neradil; Petr Karasek; Renata Veselska Journal: PLoS One Date: 2016-07-14 Impact factor: 3.240
Authors: Kyoung Su Sung; Jin-Kyoung Shim; Ji-Hyun Lee; Se Hoon Kim; Sohee Park; Tae-Hoon Roh; Ju Hyung Moon; Eui-Hyun Kim; Sun Ho Kim; Su Jae Lee; Yong Min Huh; Seok-Gu Kang; Jong Hee Chang Journal: Cancer Cell Int Date: 2016-09-27 Impact factor: 5.722